MedTrace Logo

Vaginal Progesterone Improves Clinical Outcomes of RIF Patients

NCT06005207 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2023-08-22

No results posted yet for this study

Summary

This study is a single-center, randomized, controlled prospective study. Those patients with repeated implantation failure (RIF) who will recieve frozen thawed embryo transfer (FET) are enrolled in the study. To determine the effect of vaginal progesterone on the clinical pregnancy outcomes of RIF patients.

Conditions

  • Infertility, Female

Interventions

DRUG

progesterone vaginal sustained-release gel

90 mg progesterone vaginal sustained-release gel is added daily during endometrial transformation and luteal support

Sponsors & Collaborators

  • Nanjing University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06005207 on ClinicalTrials.gov